Furthermore, treatment with IL‐7/CCL19‐expressing CAR‐T cells has been shown to induce extensive T‐cell infiltration and achieve complete rejection of GBM [87], underscoring the immune‐modulating potential of the mouse immune pericyte cluster. Here, CCL19 is linked to glioblastoma.